Hsa-miR-105-1 Regulates Cisplatin-Resistance in Ovarian Carcinoma Cells by Targeting ANXA9

Figure 5

Upregulation of Hsa-miR-105-1 inhibited ANXA9 expression in cisplatin-resistant OC cells. SW626/DDP and OVcar3/DDP cells were transfected with the scramble or Hsa-miR-105-1 mimics. (a) The levels of ANXA9 expression as detected by qPCR assays (, , and paired -test). (b) The levels of ANXA9 protein expression as detected by western blotting. (c) The distribution of ANXA9 was shown by immunofluorescence. (d) The viability of scramble or Has-miR-105-1 mimic-treated SW626/DDP or OVcar3/DDP after exposure to different concentrations of cisplatin, as detected by the CCK8 assay. (e) The IC₅₀ values for SW626/DDP and OVcar3/DDP cells treated with the scramble or Hsa-miR-105-1 mimics in cisplatin (, , and paired -test).

(a)

(b)

(c)

(d)

(e)